All News

Conv3.jpg

EULAR 2025 - Day 1 Report

Jack Cush, MD

Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.

Read Article
PMR,flag

Secukinumab promise in PMR is real

David Liew, FRACP

Choice is not just good, it is often necessary, and secukinumab promises just that in both PMR and GCA.

Read Article
GCA,woman

Secukinumab Use in Refractory Giant Cell Arteritis

Jack Cush, MD

In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab.

Read Article
2024.year.review

2024 Rheumatology Year in Review

Jack Cush, MD

2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians.  While these many advances offer new hope, they are countered by disappointments and gapping unmet needs in rheumatology. Below is my top 10 list (in no particular order) of 2024 developments and desires that may change rheumatologic practices.

Read Article
PMR,flag

BACHELOR Trial - Baricitinib in Early Polymyalgia Rheumatica

Jack Cush, MD

Lancet reports a French study demonstrating the efficacy of baricitinib in patients with polymyalgia rheumatica (PMR).

Read Article
RheumNow Podcast square

54K Peptic Ulcers Annually (12.13.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Read Article
Secukinumab promise in PMR is real GCA is getting steroid-sparing therapy choices, and PMR doesn’t want to miss out. Most PMR patients with current therapy approaches incur multiple grams of cumulative prednisolone exposure, even though they’re often exactly the kind of https://t.co/GuD0l7zSfj
Dr. John Cush RheumNow ( View Tweet)
Fast track PMR clinics in Denmark led to more patients seen, and time to referral went down. If we don’t get in early with a right diagnosis (and maybe early steroid-sparing) then PMR patients deteriorate. We shouldn’t let PMR be an end stage disease #EULAR2025 POS0136 @RheumNow https://t.co/pqwveamhJP

Links:

David Liew drdavidliew ( View Tweet)
Secukinumab for PMR? -post hoc analysis of the TitAIN study (phase 2 RCT on new onset/relapsing GCA) showed: -Numerical reduction in patients experiencing PMR symptoms when treated with secukinumab compared to placebo. -Safety profile was similar to the overall GCA study

Adela Castro AdelaCastro222 ( View Tweet)

IL-17 inhibition for PMR? In the secukinumab ph2 in GCA (TitAIN), patients with PMR did really well, seemingly outperforming steroid taper in the placebo arm. Real promise, will be great to see how the ph3 in PMR (REPLENISH) goes OP0062 #EULAR2025 @RheumNow https://t.co/cisA0GiUx1

Links:

David Liew drdavidliew ( View Tweet)
The IL-17A inhibitor, secukinumab, is in late-stage development forthe treatment of giant cell arteritis and polymyalgia rheumatica. https://t.co/JzzqS7bSjd https://t.co/9Qm0YsJmOL

Links:

Dr. John Cush RheumNow ( View Tweet)
TheDaoIndex @KDAO2011 @UnaMakris wants us to shift our approach to #GeriRheum. #RNL2025– remember the 5 M’s Multimorbidity Mind Medications Mobility what Matters most https://t.co/MIVnpw87rW https://t.co/D4AmrYhyWH

Links:

Dr. John Cush RheumNow ( View Tweet)
Adela Castro @AdelaCastro222 Are your patients aging with RA, or are they diagnosed with Late Onset RA (LORA)? -LORA pts tend to present acutely -High inflammatory markers~PMR Like -Seronegative/Decreased titers of RF/CCP @UnaMakris #RNL2025 https://t.co/tLrGBV6P1i https://t.co/53HVvUmrG4

Links:

Dr. John Cush RheumNow ( View Tweet)
TheDaoIndex @KDAO2011 Late onset RA (LORA) aka RA diagnosed at an older age — pts have higher inflammatory markers, presents like PMR; they also have polypharmacy, comorbidities, frailty, etc that can complicate management @UnaMakris #RNL2025 @RheumNow #GeriRheum… https://t.co/E2WFwfCsWD https://t.co/tKF0OnUFQH
Dr. John Cush RheumNow ( View Tweet)
@RichardPAConway on PMR #RNL2025 @RheumNow PMR mimics: look for mimics in unusual/refractory cases - Suspect the mimics to avoid undertreatment or over-treatment Conway: PMR is NOT easy. Easy to misdiagnosis, easy to mistreat. "One of our most challenging cases" https://t.co/WqPWwCuutF

Links:

Eric Dein ericdeinmd ( View Tweet)
Late onset RA (LORA) aka RA diagnosed at an older age — pts have higher inflammatory markers, presents like PMR; they also have polypharmacy, comorbidities, frailty, etc that can complicate management @UnaMakris #RNL2025 @RheumNow #GeriRheum https://t.co/zqEcyg2ejw

Links:

TheDaoIndex KDAO2011 ( View Tweet)
@UnaMakris #RNL25 @RheumNow Older patients w RA 1/3 of pts onset >60-65 - More acute onset, more systemic, more PMR-like, larger jts - Higher IL-6, lower TNF-a, less RF, higher ESR -Co-morbidities, polypharmacy, cognition, depression Age does not equal frailty, but does correlate https://t.co/5qb60WyKkP

Links:

Eric Dein ericdeinmd ( View Tweet)
Are your patients aging with RA, or are they diagnosed with Late Onset RA (LORA)? -LORA pts tend to present acutely -High inflammatory markers~PMR Like -Seronegative/Decreased titers of RF/CCP @UnaMakris #RNL2025 @RheumNow https://t.co/aOCwb3lHef

Links:

Adela Castro AdelaCastro222 ( View Tweet)
BACHELOR Trial - Baricitinib in Early Polymyalgia Rheumatica Lancet reports a French study demonstrating the efficacy of baricitinib in patients with polymyalgia rheumatica (PMR). Glucocorticoids are the mainstay of therapy in PMR patients and may be problematic in older… https://t.co/svLmE6OBWm https://t.co/K8sdROswxV
Dr. John Cush RheumNow ( View Tweet)
Great table re:side effects of even low dose steroids in RA Likely generalizes to other diseases ie PMR, SLE P in prednisone stands for poison! #ACR24 @RheumNow https://t.co/2bFy6dwl96 https://t.co/YDtjSX054I

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×